Literature DB >> 35381860

Palliation Strategy to Achieve Complete Repair in Symptomatic Neonates with Tetralogy of Fallot.

Mark A Law1, Andrew C Glatz2, Jennifer C Romano3, Paul J Chai4, Christopher E Mascio2, Christopher J Petit5, Courtney E McCracken4, Michael S Kelleman4, George T Nicholson6, Jeffery J Meadows7, Jeffrey D Zampi3, Shabana Shahanavaz8, Sarosh P Batlivala8, Joelle Pettus4, Amy L Pajk8, Kristal M Hock9, Bryan H Goldstein8,10, Athar M Qureshi11.   

Abstract

Neonates with symptomatic tetralogy of Fallot (sTOF) may undergo palliations with varying physiology, namely systemic to pulmonary artery connections (SPC) or right ventricular outflow tract interventions (RVOTI). A comparison of palliative strategies based on the physiology created is lacking. Consecutive sTOF neonates undergoing SPC or RVOTI from 2005-2017 were reviewed from the Congenital Cardiac Research Collaborative. The primary outcome was survival with successful complete repair (CR) by 18 months. A variety of secondary outcomes were assessed including overall survival, hospitalization-related comorbidities, and interstage reinterventions. Propensity score adjustment was utilized to compare treatment strategies. The cohort included 252 SPC (surgical shunt = 226, ductus arteriosus stent = 26) and 68 RVOTI (balloon pulmonary valvuloplasty = 48, RVOT stent = 11, RVOT patch = 9) patients. Genetic syndrome (29 [42.6%] v 75 [29.8%], p = 0.04), weight < 2.5 kg (28 [41.2%] v 68 [27.0%], p = 0.023), bilateral pulmonary artery Z-score < - 2 (19 [28.0%] v 36 [14.3%], p = 0.008), and pre-intervention antegrade flow (48 [70.6%] v 104 [41.3%], p < 0.001) were more common in RVOTI. Significant center differences were noted (p < 0.001). Adjusted survival to CR by 18 months (HR = 0.87, 95% CI = 0.63-1.21, p = 0.41) and overall survival (HR = 2.08, 95% CI = 0.93-4.65, p = 0.074) were similar. RVOTI had increased interstage reintervention (HR = 2.15, 95% CI = 1.36-3.99, p = 0.001). Total anesthesia (243 [213, 277] v 328 [308, 351] minutes, p < 0.001) and cardiopulmonary bypass times (117 [103, 132] v 151 [143, 160] minutes, p < 0.001) favored RVOTI. In this multicenter comparison of physiologic palliation strategies for sTOF, survival to successful CR and overall survival were similar; however, reintervention burden was significantly higher in RVOTI.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Blalock–Taussig–Thomas Shunt; Congenital heart disease; Right ventricle outflow tract intervention; Tetralogy of Fallot

Mesh:

Year:  2022        PMID: 35381860     DOI: 10.1007/s00246-022-02886-0

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.838


  22 in total

1.  Palliative balloon pulmonary valvuloplasty for infants with unrestrictive ventricular septal defect or single ventricle associated with severe pulmonary stenosis.

Authors:  Ramiro W Lizano Santamaria; Matthew J Gillespie; Yoav Dori; Jonathan J Rome; Andrew C Glatz
Journal:  Catheter Cardiovasc Interv       Date:  2015-07-08       Impact factor: 2.692

2.  Palliative shunting operations in tetralogy of Fallot. Effects upon the results of total correction.

Authors:  C A Selmonosky; D Farhangian; G M Folger; R G Ellison
Journal:  Ann Thorac Surg       Date:  1972-07       Impact factor: 4.330

3.  The efficiency of systemic-to-pulmonary shunts in older children with hypoplastic pulmonary arteries.

Authors:  Han Zhang; Xiangming Fan; Junwu Su; Yinglong Liu; Lei Zhao; Gang Li
Journal:  J Card Surg       Date:  2019-04-26       Impact factor: 1.620

4.  Right ventricular outflow tract stent versus BT shunt palliation in Tetralogy of Fallot.

Authors:  Daniel Quandt; Bharat Ramchandani; Gemma Penford; John Stickley; Vinay Bhole; Chetan Mehta; Timothy Jones; David James Barron; Oliver Stumper
Journal:  Heart       Date:  2017-08-16       Impact factor: 5.994

5.  Comparison Between Patent Ductus Arteriosus Stent and Modified Blalock-Taussig Shunt as Palliation for Infants With Ductal-Dependent Pulmonary Blood Flow: Insights From the Congenital Catheterization Research Collaborative.

Authors:  Andrew C Glatz; Christopher J Petit; Bryan H Goldstein; Michael S Kelleman; Courtney E McCracken; Alicia McDonnell; Timothy Buckey; Christopher E Mascio; Subi Shashidharan; R Allen Ligon; Jingning Ao; Wendy Whiteside; W Jack Wallen; Christina M Metcalf; Varun Aggarwal; Hitesh Agrawal; Athar M Qureshi
Journal:  Circulation       Date:  2017-10-17       Impact factor: 29.690

6.  Results of balloon pulmonary valvuloplasty as a palliative procedure in tetralogy of Fallot.

Authors:  N Sreeram; M Saleem; M Jackson; I Peart; R McKay; R Arnold; K Walsh
Journal:  J Am Coll Cardiol       Date:  1991-07       Impact factor: 24.094

7.  Early palliative balloon pulmonary valvuloplasty in neonates and young infants with tetralogy of Fallot.

Authors:  Jun Muneuchi; Mamie Watanabe; Yuichiro Sugitani; Naoki Kawaguchi; Ryohei Matsuoka; Yusuke Ando; Yoshie Ochiai
Journal:  Heart Vessels       Date:  2019-07-13       Impact factor: 2.037

8.  Evidence for palliative enlargement of the right ventricular outflow tract in severe tetralogy of Fallot.

Authors:  Bernhard Korbmacher; Andreas Heusch; Ulrich Sunderdiek; Emmeran Gams; Spiros Rammos; Mike R Langenbach; Jochen D Schipke
Journal:  Eur J Cardiothorac Surg       Date:  2005-03-23       Impact factor: 4.191

9.  Right Ventricular Outflow Tract Stenting in Tetralogy of Fallot Infants With Risk Factors for Early Primary Repair.

Authors:  Juan Pablo Sandoval; Rajiv R Chaturvedi; Lee Benson; Gareth Morgan; Glen Van Arsdell; Osami Honjo; Christopher Caldarone; Kyong-Jin Lee
Journal:  Circ Cardiovasc Interv       Date:  2016-12       Impact factor: 6.546

10.  Stenting of the Right Ventricular Outflow Tract Promotes Better Pulmonary Arterial Growth Compared With Modified Blalock-Taussig Shunt Palliation in Tetralogy of Fallot-Type Lesions.

Authors:  Daniel Quandt; Bharat Ramchandani; John Stickley; Chetan Mehta; Vinay Bhole; David J Barron; Oliver Stumper
Journal:  JACC Cardiovasc Interv       Date:  2017-09-11       Impact factor: 11.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.